Table 1.
| Patient Characteristic | NHW, n (%) | AA, n (%) | P Value |
|---|---|---|---|
| Age at diagnosis | .001 | ||
| 50–64 | 435 (43.3) | 207 (53.0) | |
| 65–74 | 371 (56.7) | 161 (47.0) | |
| Registry | .0000 | ||
| Connecticut | 401 (36.4) | 45 (14.8) | |
| Atlanta | 128 (19.2) | 103 (30.6) | |
| Los Angeles | 277 (44.4) | 220 (54.6) | |
| Marital status | .0000 | ||
| Not married | 134 (16.7) | 110 (29.5) | |
| Married | 665 (82.4) | 254 (69.3) | |
| Education | <.0001 | ||
| Less than high school graduate | 95 (11.7) | 121 (34.4) | |
| High school graduate/some college | 333 (41.7) | 174 (45.8) | |
| College graduate | 371 (45.4) | 66 (17.9) | |
| Insurance influenced treatment decision | .01 | ||
| Not at all | 613 (74.9) | 249 (67.4) | |
| Only a little/somewhat | 108 (13.0) | 44 (11.8) | |
| A lot | 73 (10.6) | 63 (17.6) | |
| Comorbidity index | <.0001 | ||
| 0 | 349 (40.3) | 109 (29.3) | |
| 1 | 267 (34.8) | 103 (27.6) | |
| 2 | 116 (13.9) | 88 (23.2) | |
| 3+ | 74 (11.0) | 68 (19.9) | |
| Urinary leakage | .05 | ||
| Daily or more | 62 (8.0) | 40 (11.8) | |
| Weekly or less | 73 (10.4) | 39 (10.1) | |
| Not at all | 666 (81.6) | 281 (76.1) | |
| Urgent bowel movements | .91 | ||
| Almost everyday | 8 (1.3) | 6 (1.8) | |
| Some days | 117 (13.4) | 50 (14.4) | |
| Rarely/not at all | 677 (84.5) | 309 (83.1) | |
| Erections | .56 | ||
| None | 68 (10.0) | 40 (12.6) | |
| Partial only | 104 (13.6) | 50 (14.8) | |
| Hard/hard and partial | 609 (73.2) | 264 (68.9) | |
| Abnormal DRE | .18 | ||
| No | 318 (39.2) | 155 (42.5) | |
| Yes | 409 (51.0) | 166 (45.1) | |
| PSA (ng/mL) | <.0001 | ||
| <10.0 | 562 (70.1) | 197 (53.6) | |
| 10.0–19.9 | 141 (17.2) | 76 (20.9) | |
| ≥20.0 | 72 (8.6) | 73 (19.6) | |
| Gleason score | .35 | ||
| 2–4 | 107 (12.7) | 49 (13.1) | |
| 5–7 | 580 (71.9) | 245 (67.1) | |
| 8–10 | 71 (8.2) | 39 (10.7) | |
| Tumor aggressiveness | .0002 | ||
| PSA ≥ 20 ng/mL or Gleason ≥ 8 | 128 (15.1) | 94 (25.4) | |
| PSA < 20 ng/mL and Gleason < 8 | 609 (75.1) | 229 (62.9) | |
| Bone scan | .12 | ||
| Negative | 520 (63.2) | 218 (60.3) | |
| Equivocal | 54 (6.0) | 14 (3.8) | |
| Not done/unknown | 232 (30.9) | 136 (35.8) |
*
Weighted to reflect all eligible prostate cancer patients in the study area.
†
Column percentages may not total to 100% owing to missing data.
NHW, non-Hispanic white; AA, African American; DRE, digital rectal examination; PSA, prostate-specific antigen.